<DOC>
	<DOCNO>NCT00515229</DOCNO>
	<brief_summary>Our data indicate CFTR-molecule function transporter sphingosine-1-phosphate sphingosine regulates uptake sphingolipids epithelial cell . The disturbed uptake sphingosine sphingosine-1-phosphate cell membrane result accumulation ceramide cell membrane , finally trigger pro-inflammatory pro-apoptotic status respiratory tract cystic fibrosis patient . Amitriptyline reduce cera-mide level lung tissue , normalise activity cytokine prevents constitutive cell death epithelial cell observe CFTR-deficient mouse . Most important , amitriptyline prevents pulmonary infection CFTR-deficient mouse P. aeruginosa . These effect amitriptyline may result improved lung function cystic fibrosis patient .</brief_summary>
	<brief_title>Anti-Inflammatory Pulmonal Therapy CF-Patients With Amitriptyline Placebo</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) , common autosomal recessive disorder least western country , cause mutation cystic fibrosis transmembrane conductance regulator molecule ( CFTR ) affect approximately 40 000 patient Europe . Most , , CF-patients develop chronic pulmonary infection Pseudomonas aeruginosa ( P. aeruginosa ) . At present un-known CF-patients highly sensitive P. aeruginosa infection , important , curative treatment cystic fibrosis available . Our data CFTR-deficient mouse demonstrate CFTR-molecule function chloride-channel , also transporter sphingolipids , particular sphingosine sphingosine-1-phosphate . Deficiency functional CFTR CFTR-knock-out mouse result alteration sphingolipid metabolism pulmonary epithelial cell accumulation cellular ceramide cell . Inhibition ceramide release lung achieve pharmacological genetic inhibition acid sphingomyelinase ( ASM ) generate ceramide sphingomyelin . Amitriptyline employ pharmacologically block ASM genetic inhibition ASM achieve cross CFTR- ASM-deficient mouse . Although ASM affect cystic fibrosis , inhibition enzyme block formation ceramide , thus , normalize increase pulmonary ceramide cause CFTR-deficiency .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1 . Cystic Fibrosis prove 2 . The patient old 18 year ( &lt; 50 year ) 3 . No sec discrimination 4 . The patient pulmonal colonize bacteria 5 . Signs pulmonary exacerbation present 6 . A full course therapy possible without restriction 7 . Lung function measurement possible 1 . Poor metabolizer amitriptyline ( CYP2D6 genotyping ) 2 . Glaucoma , seizures , heart insufficiency depression present 3 . Signs acute pulmonary illness ( bronchial tracheal stenosis , tuberculosis , thorax trauma , acute pneumonia , pneumothorax , bronchial haemorrhage , ARDS ) present 4. intravenous antibiotic treatment necessary last 4 week 5 . Involvement patient another study 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>ceramide</keyword>
	<keyword>amitriptyline</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>lung function</keyword>
</DOC>